Key Highlights

  • Paysign (NASDAQ:PAYS) dropped 18.94% on November 10, 2026 even with record Revenue up 43%, after a plasma customer said it would shift 113 centers to a different provider.
  • EquipmentShare declined 16.50% although revenue grew 55% to USD 1.468 billion, with long-term Debt climbing to USD 4.227 billion.
  • Novanta lost 15.26% after a fourth-quarter profit guide landed below consensus, while Boyd Group lost 12.79% on November 11 as net Earnings fell 99%.
  • Legend Biotech slid 16.53% because US Carvykti sales rose just 19%, even though overall growth was 36%.

1. Paysign (NASDAQ:PAYS): Strongest Case for a Recovery

On November 10, Paysign (NASDAQ:PAYS) closed 18.94% lower after revealing that a plasma customer will transfer payment processing for 113 centers to another provider by year-end. The quarter itself was excellent: third-quarter revenue grew 43% to a record USD 30.8 million, pharma revenue more than doubled to USD 16.62 million, gross Margin widened to 64.7% and Net Income tripled to USD 6.74 million. Over the last 12 months the departing centers generated USD 11.3 million of revenue and USD 5.2 million of gross profit, the fourth-quarter revenue impact is about USD 1.5 million, and the center count should drop to 445 to 450 from 562. Even so, 2026 revenue guidance was held at USD 114.0 million to USD 117.0 million, and the profit outlook went up, including adjusted EBITDA of USD 38.5 million to USD 40.0 million and net income of USD 23.0 million to USD 24.0 million. Pharma grew 109.8%, with 167 active patient affordability programmes today and 190 to 195 expected by year-end, each of which adds recurring revenue. There is no bank debt, and cash stands at USD 34.54 million. What matters is whether the plasma loss reflects one customer's choice or the start of a trend as operators consolidate. Rapid pharma growth could Fill the revenue gap within a year.

2. EquipmentShare (NASDAQ:EQPT): Growth Funded by Leverage

Despite total revenue up 55% to USD 1.468 billion, rental revenue up 49% to USD 1.113 billion and equipment sales up 76%, EquipmentShare (NASDAQ:EQPT) finished November 10 down 16.50%, having been off as much as 22.33% in the morning. No explanation came from the company. Market Participants seem to have fixated on what growth costs. Long-term debt grew to USD 4.227 billion from USD 3.268 billion at year-end, interest expense went to USD 88 million from USD 75 million, and net income was a slim USD 20 million, or USD 0.03 per share. Funding is not under immediate strain, as net Leverage improved to 3.4 times from 3.7 times and Liquidity was USD 2.298 billion. The OWN Program is a distinctive element: outside investors purchase equipment that the company then rents out, and sales to participants form a meaningful share of equipment sales, which some see as less durable than rental income. Rental is cyclical and tied to construction activity, although data centers and factories help support demand. As a recent listing, the stock also faces potential share Supply from insiders. Fleet utilisation and leverage deserve the closest attention. Canadian investors can reach this US-listed name through a domestic brokerage account.

3. Novanta (NASDAQ:NOVT): A Strong Quarter Overshadowed by Guidance

Fourth-quarter adjusted earnings guidance of USD 0.91 to USD 0.96 per share, well under a consensus near USD 1.02, sent Novanta (NASDAQ:NOVT) down 15.26% on November 10, after an intraday low of 17.6% below the prior close. The reported quarter was strong. Revenue grew 23.1% to USD 305.0 million with organic growth of 9.9%, bookings jumped 29%, Backlog hit USD 543 million and adjusted earnings improved to USD 1.05 per share from USD 0.87. On a GAAP basis, Operating Margin slipped to 4.6% from 8.8% and earnings fell to USD 0.05 per share, as Acquisition costs and Amortisation climbed following the Riverpoint Medical purchase, the company's biggest deal. Net debt rose to about USD 689.4 million. Novanta supplies precision motion, photonics and medical components used in robotics and surgical systems, and management is looking for reported revenue growth above 15% in 2027. Full-year 2026 guidance is for revenue of USD 1.135 billion to USD 1.14 billion, with organic growth near 7%. Near-term earnings power mattered more to investors than order strength. The open questions are whether Riverpoint raises margins in 2027, whether medical Demand holds, and how quickly debt comes down.

4. Boyd Group Services (NYSE:BGSI): Acquisition Costs Hit Earnings

Third-quarter sales at Boyd Group Services (NYSE:BGSI) grew 28.2% to USD 1.013 billion, driven largely by the Joe Hudson's Collision Center acquisition, yet the stock ended November 11 down 12.79%. Net earnings dropped 99% to USD 81 thousand, and adjusted Earnings Per Share fell 18% to USD 0.68. The pressure arrived below the operating line: finance costs went to USD 32.3 million from USD 18.8 million because of acquisition debt, and an Equity issue lifted the share count to about 27.8 million from 21.5 million, even as adjusted net earnings gained 6%. Adjusted EBITDA increased 34.3% to USD 132.1 million. Same-store sales rose 2.2%, a touch under last year's 2.4%, which suggests a soft collision repair market where fewer Insurance Claims and deferred repairs hold back volumes. October same-store growth stayed positive. The underlying trend looks better than this quarter: nine-month adjusted earnings per share improved to USD 2.06 from USD 1.85, the company has captured USD 50 million of cost savings against a USD 65 million target for 2026, and share Buybacks have begun. Interest costs will remain high until debt is reduced, and insurance partners are still central to volumes.

5. Legend Biotech (NASDAQ:LEGN): Good Quarter, Higher Bar

In afternoon trading on November 10, Legend Biotech (NASDAQ:LEGN) was down 16.53%, even though Carvykti, the multiple myeloma CAR-T therapy it shares with Johnson & Johnson, lifted net trade sales 36% to about USD 710 million. US sales rose only 19% compared with 86% outside the US, signalling slower momentum in the biggest market, where bispecific antibodies compete. Operating Cash Flow was negative USD 35.9 million. On the other hand, total revenue grew 32% to USD 359.5 million, the company turned to net income of USD 51.7 million from a loss of USD 39.6 million, and Operating Income reached USD 46.8 million as research and administrative costs declined. Full-year profitability in 2026 is on track, and cash and deposits are about USD 853 million. Carvykti is offered at 373 sites in 20 markets, five-year data showed median progression-free survival of 60.5 months in one cohort, and updated guidelines prefer CAR-T when both Options are viable. Ingrid Zhang, the new chief executive, oversees a pipeline that includes an in vivo CAR-T candidate cleared by the FDA. After a long run of beats, expectations had climbed, so even a good quarter appeared light. Manufacturing capacity continues to cap the number of patients treated.

Where Things Stand

Paysign has the strongest rebound case among these five Growth Stocks that fell, as it held revenue guidance, raised profit guidance, carries no bank debt and has a fast-growing pharma segment able to replace the lost plasma revenue. Legend Biotech has a comparable profit path but needs a US reacceleration, Novanta and Boyd bear acquisition debt costs, and EquipmentShare is the most heavily leveraged. Next quarterly results and any further plasma customer news will show whether the declines went too far.